目前尚无年轻发病巴雷特食管 (BE) 患者的癌症进展风险和终生风险数据。我们的目的是通过收集 1991 年 1 月 1 日至 2015 年 12 月 31 日长达 25 年间所有组织学确诊病例的数据，获得荷兰年轻发病 BE 中不典型增生或腺癌发病率的流行病学数据。来自荷兰国家病理学登记处。如果在内窥镜检查期间怀疑食管内出现 BE，并结合一致的肠化生组织学诊断，则纳入患者。 确定了 231 名早发 BE 患者（中位年龄 26 岁 [范围 0-29 岁]） ，其中 17 例进展为发育不良（6 例为普遍病例，11 例为偶发病例）。对于偶发性不典型增生的患者，诊断早发BE和诊断不典型增生之间的中位监测时间为5年（范围0-16年）。不典型增生的发生率为每1000人年7.3人。有 3 名患者罹患腺癌（1 名患病患者和 2 名偶发患者），诊断年龄分别为 28 岁、35 岁和 36 岁。腺癌的发病率为每1000人年1.3例。在这25年期间，荷兰有231名患者被诊断为早发BE，其中17名患者进展为不典型增生，3名患者发展为腺癌。这相当于每 1000 人年 7.3 例不典型增生的发病率和每 1000 人年 1.3 例腺癌的发病率。作者。这是 Thieme 根据知识共享署名许可条款发表的开放获取文章，只要正确引用原始作品，就允许不受限制地使用、分发和复制。 （https://creativecommons.org/licenses/by/4.0/）。

Currently data on the risk of progression to and lifetime risk of cancer are not available for patients with young onset Barrett's esophagus (BE). Our aim was to obtain epidemiologic data on the incidence of dysplasia or adenocarcinoma in young onset BE in the Netherlands by collecting data on all histologically confirmed cases over a prolonged period of 25 years between January 1, 1991 and December 31, 2015.Data were obtained from the Dutch National Pathology Registry. Patients were included if there was a suspicion of BE visualized in the esophagus during the endoscopic examination in combination with a concordant histologic diagnosis of intestinal metaplasia.231 patients with early onset BE were identified (median age 26 years [range 0-29 years]), with 17 progressing to dysplasia (6 prevalent and 11 incident). For the patients with incident dysplasia, the median surveillance time between the diagnosis of early onset BE and diagnosis of dysplasia was 5 years (range 0-16 years). The incidence rate of dysplasia was 7.3 per 1000 person-years. There were three patients who developed adenocarcinoma (1 prevalent and 2 incident), who were diagnosed at ages 28, 35, and 36 years. The incidence rate of adenocarcinoma was 1.3 per 1000 person-years.In this 25-year period, 231 patients were diagnosed with early onset BE in the Netherlands, with 17 patients progressing to dysplasia and three developing adenocarcinoma. This corresponded to incidence rates of 7.3 per 1000 person-years for dysplasia and 1.3 per 1000 person-years for adenocarcinoma.The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).